| Publicación: |
[Barcelona] : Universitat Autònoma de Barcelona, 2013 |
| Descripción: |
1 recurs electrònic (135 p.) |
| Resumen: |
Aromatase inhibitors are the gold standard treatment for postmenopausal women with early breast cancer (EBC). The major side effects are bone loss and arthralgias, that can induce treatment discontinuations. Baseline bone health in postmenopausal women is poorly characterised in prospective series of EBC patients candidates to AI therapy. Our objective is to comprehensively evaluate bone health in a prospective clinical cohort of patients recruited prior to adjuvant AI therapy, with the aim of establishing potential AI impact on bone loss and fractures. We consecutively included 343 women with EBC who were about to start adjuvant AI therapy. Participants were assessed before AI initiation and at 3 months, with annual assessments thereafter. Bone mineral density (BMD), spine X-ray, bone metabolism (vitamin D, bone turnover markers), arthralgia and quality of life are measured. The results of our study demonstrates: - Treatment with adjuvant AI decreases BMD 0. 6 at 2. 36% at 12 months, even thought calcium and vit D treatment were administered following the guidelines. - When patients starts AI the asymptomatic fragility fractures rate was 11. 8%. - Baseline vit D levels are suboptimal. Vitamin D insufficiency ( 40 ng/ml. - Bone loss at 12 months is not observed in women on oral bisphosphonates treatment. |
| Nota: |
Tesi doctoral - Universitat Autònoma de Barcelona. Departament de Medicina, 2012 40 ng/ml. - Les dones que reben bisfosfonats orals durant el tractament amb IA no presenten pèrdua de massa òssia als 12 mesos. 40 ng/ml. - Les dones que reben bisfosfonats orals durant el tractament amb IA no presenten pèrdua de massa òssia als 12 mesos |
| Derechos: |
Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.  |
| Lengua: |
Català |
| Documento: |
Tesi doctoral ; Versió publicada |
| Materia: |
Càncer mama ;
Inhibidors aromatasa ;
Salut òssia |
| ISBN: |
9788449033131 |
visitante ::
identificación
